Good news! Yaohai Bio-Pharma has recently passed the on-site audit by the European Union Qualified Person (QP) for the GMP quality system and production site. Additionally, it has cleared the initial
Yaohaibio Sterile PreparationsService AbilityIn March 2022 the new production line of Yaohaibio macromolecular drug R&D and production service was put into operation, including a new sterile produ
Frost & Sullivan (Frost & Sullivan, abbreviated as “Sullivan”) officially issued the Research Report on the Development Status and Future Trends of CDMO Industry (hereinafter referred to as th
Customized Preparation Service of Research-Grade mRNA SamplesThe outbreak of the new crown epidemic in 2020 has brought mRNA technology to the forefront. mRNA vaccines and drugs have attracted worldwi
Yaohaibio’s Full Ecological Recombinant Expression System of NanobodyFull-range customization servicesNanobody (Nb), namely VHH (variable domain of heavy chain of heavy-chain antibody), was first repo
CRO Services for Novel Circular RNA TherapiesOfficially launchedIn the recent two years, with the successful development of new mRNA COVID-19 vaccines and the approval of several new RNA-based drugs,
The trend of synthetic biology has ushered in changes in the pharmaceutical industrySynthetic biology could one of the most rapidly developing cutting-edge interdisciplinary fields in recent years. Th
As a leader in CDMO services focusing on microbial expression systems in China, Yaohaibio focuses on the fields of “recombinant protein/peptide, nucleic acid drugs, nanoantibodies, novel recombinant vaccines”, etc., and is committed to building an open an
Since the outbreak of COVID-19 epidemic in 2020, mRNA technology has received unprecedented attention and the development of COVID-19 vaccine has made mRNA familiar and the research on it has never be
Company News